Lantern Pharma Inc. (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," covering the use of its drug candidate LP-284 to treat mantle cell lymphoma (MCL) and double-hit lymphoma (DHL).

The allowed claims cover LP-284 administered as a monotherapy and in combination with a second anti-cancer agent, including DNA damaging agents, glucocorticoids, immunomodulatory drugs, BCL2 inhibitors, BTK inhibitors, spironolactone, PARP inhibitors, and proteasome inhibitors. The claims also cover intravenous and intraperitoneal routes of administration. Once issued, following payment of the required fee, the patent is expected to extend LP-284 protection into 2042.

The new allowance builds on Lantern's existing LP-284 composition-of-matter patent estate, which provides protection into 2039 across markets including the United States, European Union, Japan, China, India, Mexico, Korea, and Australia. Lantern received its first U.S. composition-of-matter Notice of Allowance for LP-284 in April 2023, a Certificate of Patent from the Japan Patent Office in June 2024, and a European Patent Office allowance in July 2025.

LP-284 holds three FDA Orphan Drug Designations: for MCL, for high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and for soft tissue sarcomas. The drug candidate is currently being evaluated in an ongoing Phase 1a dose-escalation clinical trial (NCT06132503) in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas and solid tumors.

According to the company's press release, a patient with aggressive diffuse large B-cell lymphoma who had failed three prior treatment regimens, including CAR-T cell therapy, achieved a confirmed complete metabolic response after two cycles of LP-284. The company reported that LP-284 has been well tolerated to date, with primarily Grade 1–2 adverse events.